Schizophrenia News: January 2013
The U.S. Food and Drug Administration (FDA) approved Adasuve (loxapine) for the acute treatment of agitation caused by schizophrenia or bipolar 1 disorder. Adasuve is the first non-injectable form of therapy for symptoms of agitation. Two phase 3 clinical trials involving 1,600 patients were carried out with either Adasuve or... Read more



10 Things Not to Say to Someone With Depression
6 Behavior Changes During Depression
Getting to Know Your 5 Essential Brain Chemicals
10 Surprising Ways to Enhance Your Mind